YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)


AddThis Social Bookmark Button
Injured by Xigris?

Eli Lilly and Co.'s sepsis treatment Xigris has been the focus of intense scrutiny since the U.S. Food and Drug Administration approved it in November 2001.  It was approved despite an FDA advisory panel's split decision on whether or not to recommend approval. The FDA has required Lilly to conduct a number of additional trials, including a current study of adult patients with severe sepsis who were at low risk of death.

A drug approved in the United States for treating severe sepsis, Xigris is linked to an often-fatal blood infection accompanied by acute organ failure.  For less severely ill septic patients, drotrecogin alfa (activated), the first bioengineered drug therapy for the treatment of sepsis, appears to be no more effective than a placebo in reducing death. It also poses a serious risk of bleeding and should not be used, an international research team has concluded. The multi-center trial to test the effects of the drug in low death-risk patients was terminated early when an interim analysis of data showed little chance it would reduce the risk of death.

"Here's a drug that's potentially harmful, that causes increased bleeding episodes in patients, and if there's no evidence of any benefit, really the appropriate thing to do is to stop the study," explained lead author Dr. Edward Abraham, co-head of the division of pulmonary sciences and critical care medicine at the University of Colorado Health Sciences Center in Denver.

Severe sepsis kills 215,000 people in the United States each year, according to the Society of Critical Care Medicine. It often develops from infections associated with pneumonia, trauma, surgery, burns, or cancer, and can cause clotting and inflammation in the blood vessels. Drotrecogin alfa (activated) is a genetically engineered version of the activated protein C, a naturally occurring substance that regulates blood clotting, controls inflammation, and helps break down clots.

If you or a loved one took Xigris and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
XigrisRSS Feed

Xigris Linked to Increased Risk of Deaths, FDA Announces Safety Review

Feb 4, 2009 | Parker Waichman Alonso LLP
Xigris, a treatment for sepsis made by Eli Lilly, is now the subject of a Food & Drug Administration (FDA) safety review.  The review was prompted by a study that showed Xigris (known generically as Drotrecogin alfa)  increased the risk of dangerous internal bleeding when used by patients with a recent history of hemorrhages.Xigris is similar to a natural protein produced by the body. In patients with severe, life-threatening sepsis, Xigris decreases inflammation and the formation...

More Xigris News

Xigris
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2010 YourLawyer.com®. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising